AI Drug Discovery for Pharma and Biotech

Drug discovery

8

papers

On emerging therapies

Overview

Familial Scaphocephaly Syndrome is a rare craniosynostosis disorder characterized by premature fusion of the sagittal suture, leading to scaphocephaly (elongated skull), macrocephaly, severe maxillary retrusion, and mild intellectual disability in some cases. It is caused by a FGFR2 K526E mutation and follows autosomal dominant inheritance [7][15]. Diagnosis involves clinical evaluation, imaging, and genetic testing.

Population

  • Rare: Reported in ~11 individuals across three generations in one family and sporadic cases [7][15].

  • Accounts for <9% of familial craniosynostosis, with sagittal synostosis being the most common type (40–58% of non-syndromic cases) [4][17].

Burden

  • Physical: Risk of raised intracranial pressure (20–44%), skull deformities, and surgical complications (blood loss, reoperations) [12][8].

  • Developmental: Up to 37% experience speech delays; mild intellectual disability in severely affected males [7][12].

  • Psychosocial: Potential psychological impacts on self-esteem and family stress due to craniofacial differences [12][7].

Therapies

  • Early surgery: Endoscopic strip craniectomy with helmet therapy (before 4 months) or open cranial vault remodeling (after 4 months) [3][13][8].

  • Multidisciplinary care: Includes neurosurgeons, craniofacial specialists, and speech therapists to address developmental delays [12].

  • Genetic counseling: Recommended for families with identified FGFR2 mutations to discuss recurrence risks [7][15].

Categories: rare bone diseases, rare developmental anomalies during embryogenesis, rare genetic diseases

Research Papers

8 drug discovery papers about Familial scaphocephaly syndrome. Recent publications:

8 drug discovery papers about Familial scaphocephaly syndrome. Recent publications:

categories:

Small molecules

proteins
2025-12-22 | Surgeon- and parent-reported outcome after surgery for craniosynostosis.

While previous studies have focused on quantitative assessments and surgeon-reported surgical outcomes, limited research exists on parent-reported outcomes following surgical correction of craniosynostosis. Our study assessed both surgeon-assessed and parent-reported outcomes in children who underwent craniosynostosis correction surgery. A retrospective observational study analyzed the outcomes of 103 children who underwent craniosynostosis surgery between January 2009 and June 2022. First the surgeon assessed the outcome using the Sloan outcome classification system, which ranks cosmetic results on a six-point ordinal scale ranging from excellent correction (Class 1) to compromised correction requiring revision surgery (Class 7). Second, a non-structured patient-reported outcome measurement (PROM) evaluating subjective postoperative changes in cosmetic appearance, vision, oropharyngeal symptoms, scholastic performance, and quality of life (QOL) for both the child and parent was carried out. PROM responses were categorized as A (worsened), B (unchanged), C (moderately improved), or D (significantly improved). Fifty-eight children (56.3 %) achieved a Sloan Class 1 outcome, indicating excellent correction with no visible or palpable deformity. Children with metopic suture synostosis showed the highest improvement (85.7 %). Subjective outcome assessment using PROM revealed statistically significant differences between syndromic (S) and nonsyndromic (NS) craniosynostosis groups across multiple domains. There was a strong correlation between surgeon-reported outcomes and PROM domains of cosmesis, as well as parent and child quality of life. Our study highlights the importance of incorporating both objective and subjective measures in assessing outcomes of craniosynostosis surgery.

Open article ↗



proteins
2025-12-22 | Surgeon- and parent-reported outcome after surgery for craniosynostosis.

While previous studies have focused on quantitative assessments and surgeon-reported surgical outcomes, limited research exists on parent-reported outcomes following surgical correction of craniosynostosis. Our study assessed both surgeon-assessed and parent-reported outcomes in children who underwent craniosynostosis correction surgery. A retrospective observational study analyzed the outcomes of 103 children who underwent craniosynostosis surgery between January 2009 and June 2022. First the surgeon assessed the outcome using the Sloan outcome classification system, which ranks cosmetic results on a six-point ordinal scale ranging from excellent correction (Class 1) to compromised correction requiring revision surgery (Class 7). Second, a non-structured patient-reported outcome measurement (PROM) evaluating subjective postoperative changes in cosmetic appearance, vision, oropharyngeal symptoms, scholastic performance, and quality of life (QOL) for both the child and parent was carried out. PROM responses were categorized as A (worsened), B (unchanged), C (moderately improved), or D (significantly improved). Fifty-eight children (56.3 %) achieved a Sloan Class 1 outcome, indicating excellent correction with no visible or palpable deformity. Children with metopic suture synostosis showed the highest improvement (85.7 %). Subjective outcome assessment using PROM revealed statistically significant differences between syndromic (S) and nonsyndromic (NS) craniosynostosis groups across multiple domains. There was a strong correlation between surgeon-reported outcomes and PROM domains of cosmesis, as well as parent and child quality of life. Our study highlights the importance of incorporating both objective and subjective measures in assessing outcomes of craniosynostosis surgery.

Open article ↗



Access all drug discovery papers and probability of success in trials forecasts:

Access all drug discovery papers and probability of success in trials forecasts:

Drug Discovery Landscape

0 orphan drug designations.

0 orphan drug designations.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.